Full text is available at the source.
Abstract
Advancements in CAR T cell therapy for solid tumors face challenges related to antigen diversity and tumor microenvironment.
- CAR T cell therapy has achieved notable success in blood cancers but struggles with solid tumors.
- Factors limiting effectiveness include varied antigens and the suppressive environment around tumors.
- Strategies to improve CAR T cell function in solid tumors include enhancing T cell longevity and targeting multiple antigens.
- Combining CAR T therapies with immune checkpoint inhibitors may help counteract the tumor microenvironment's negative effects.
- Ongoing research is essential to refine treatment methods and meet the needs of cancer patients.
Simplified